N/A N=776 A Retrospective Evaluation of Superficial Radiation Therapy (SRT) and Non-Melanoma Skin Cancer (NMSC)
Non-melanoma Skin Cancer
Primary: Cure Rate — 751 lesions
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=162 Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Actinic Keratosis · Warts · Basal Cell Carcinoma
Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120
N/A N=33 Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma. — 28 tumors
N/A N=75,771 Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo
Vitiligo · Melanoma (Skin) · Nonmelanoma Skin Cancer
Primary: Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo — 133; 812 Participants
Phase 3 N=102 Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT Cycle — 80 percentage of participants
Phase 4 N=86 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
Skin Neoplasms · Kidney Transplantation
Primary: New Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year — 1.31; 2.48 Standardized Yearly Rate of NMSC — p=0.022
Phase 2 N=12 Preventing Squamous Cell Skin Cancer
Squamous Cell Carcinoma of the Skin
Primary: Mean Number of Squamous Cell Carcinomas — 0.75; 1.00 # of squamous cell carcinomas — p=0.750
Phase 3 N=120 Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma
Superficial Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT or Cryotherapy Cycle — 92; 90 percentage of…
Phase 2 N=100 Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo
Patients at Risk for Melanoma
Primary: UV-induced Oxidative Stress in Irradiated and Unirradiated Nevi — 94.6; 96.2; 33.6; 33.1 percentage of 8-OG expression in nevi — p=.65
Phase 2 N=20 Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study
Carcinoma, Basal Cell
Primary: Change in Occurence of Local Skin Reaction (LSR) Side Effects TOTAL COMPOSITE SCORE — 7; 9; 4; 2 score on a scale
Phase 3 N=66 PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma
Basal Cell Carcinoma
Primary: Percentage of Participants With Histologically Confirmed Complete Response (CR) — 67; 18 percentage of participants — p=<0.001
N/A N=54 Enhancing Skin Cancer Early Detection and Treatment in Primary Care
Cutaneous Melanoma
Primary: Change in Clinician Knowledge in Melanoma Risk and Lesion Identification — 72.1; 80.8 score on a scale — p=0.05
N/A N=54 Skin Care Behaviors Among Melanoma Survivors and Their Families
Melanoma
Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants
N/A N=30 CellFX Treat & Resect Low-Risk BCC Feasibility Study
BCC - Basal Cell Carcinoma · BCC · Excision Margin
Primary: Number of Lesions With BCC Histological Clearance — 34 BCC Lesions
Phase 3 N=65 Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: Number of Participants With Histologically Confirmed Complete Response — 25; 11 Participants
N/A N=11 Effect of Dermal Rejuvenation on the UVB Response of Geriatric Skin
Pre-cancerous Geriatric Skin
Primary: Difference in Basal Layer Keratinocytes Positive for Both Ki67 and Thymine Dimers — 21.5; 14.7 positive cells/1000 basal layer cells
Phase 4 N=954 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Carcinoma, Basal Cell · Carcinoma, Squamous Cell · Skin Neoplasms
Primary: The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed — 3.37; 3.52 years — p=0.93
N/A N=183 Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx
Non-melanoma Skin Cancer
Primary: Local Recurrence — 2 Lesions
N/A N=81 Correlation Between Skin Carotenoid Levels and Previous History of Skin Cancer
Skin Cancer · Basal Cell Carcinoma · Squamous Cell Carcinoma
Primary: Skin Carotenoid Levels in Subjects With History of Squamous Cell Carcinoma Versus Control Subjects — 27,635; 31,219 Raman spectroscopy intensity counts — p=0.31
N/A N=14,381 The Impact of Total Body Skin Examination on Skin Cancer Detection
Melanoma · Basal Cell Carcinoma · Squamous Cell Carcinoma
Primary: Number of Participants With Suspicious Tumors Detected After Inspection of Problem Area and Inspection of the Full Body. — 810; 631 participants — p=<0.01
N/A N=600 Skin Health Online for Melanoma: Better Risk Assessment
Melanoma (Skin)
Primary: Reach of Personalized Genomic Testing for Melanoma. — 0; 204; 0; 295 Participants
Phase 2 N=36 Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face
Neoplastic Syndrome
Primary: Complete Response Rate — 2 Participants
Phase 1 N=22 Topical Myristyl Nicotinate Cream on the Skin of Healthy Volunteers
Healthy
Primary: Participants With Adverse Events by Treatment. — 8; 2 participants — p=0.01
N/A N=420 Skin Self-Examination Education During Mammography
Melanoma
Primary: Number of Participants That Performed a Skin Self-Examination at 3-months — 161; 185 Participants — p=0.12
Phase 2 N=34 Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back
Skin Carcinoma
Primary: Number of Participants With Reduction in the Observed Numbers of Basal Cell Carcinomas ≥ 9 mm² in Diameter — 5; 29 participants
N/A N=12 Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser
Nodular Basal Cell Carcinoma · Superficial Basal Cell Carcinoma
Primary: Percentage of Lesions Cleared Histologically — 3; 5 Lesion
N/A N=368 Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors
Melanoma (Skin)
Primary: Sun Protection Habits Index — 2.9; 3 scores on a scale
Phase 3 N=169 Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream
Superficial Basal Cell Carcinoma
Primary: Number of Participants With Sustained Clearance Rate of Superficial Basal Cell Carcinoma (sBCC) — 119 participants
N/A N=369 Comparison of eBX and Mohs Surgery for Treatment of Early-stage Non-melanoma Skin Cancer a Matched Pair Cohort Study.
Nonmelanoma Skin Cancer
Primary: Absence of Local Recurrence at Treatment Site(s) Greater or Equal to 3 Years Follow-up — 188; 181; 187; 181 participants
N/A N=24 Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers
Melanoma, Skin
Primary: Number of Genes That Showed Changes in Expression After Vitamin D Treatment — 270 number of genes